Ligand Pharmaceuticals (LGND) Projected to Post Quarterly Earnings on Thursday

Ligand Pharmaceuticals (NASDAQ:LGND) will likely be releasing its Q4 2025 results before the market opens on Thursday, February 26th. Analysts expect Ligand Pharmaceuticals to post earnings of $1.46 per share and revenue of $55.5890 million for the quarter. Investors may review the information on the company’s upcoming Q4 2025 earning report for the latest details on the call scheduled for Thursday, February 26, 2026 at 8:30 AM ET.

Ligand Pharmaceuticals Price Performance

Shares of NASDAQ LGND opened at $189.00 on Wednesday. The company has a market capitalization of $3.72 billion, a PE ratio of 91.30 and a beta of 1.14. The company has a quick ratio of 24.30, a current ratio of 24.69 and a debt-to-equity ratio of 0.47. The stock’s 50 day moving average price is $193.61 and its 200-day moving average price is $184.88. Ligand Pharmaceuticals has a twelve month low of $93.58 and a twelve month high of $212.49.

Insider Activity

In related news, CFO Octavio Espinoza sold 1,804 shares of the company’s stock in a transaction that occurred on Friday, December 12th. The shares were sold at an average price of $188.31, for a total transaction of $339,711.24. Following the sale, the chief financial officer directly owned 26,186 shares in the company, valued at approximately $4,931,085.66. This represents a 6.45% decrease in their position. The sale was disclosed in a filing with the SEC, which can be accessed through this hyperlink. Also, Director John W. Kozarich sold 467 shares of the firm’s stock in a transaction that occurred on Monday, February 2nd. The stock was sold at an average price of $195.91, for a total transaction of $91,489.97. Following the completion of the transaction, the director directly owned 43,187 shares of the company’s stock, valued at approximately $8,460,765.17. This trade represents a 1.07% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Over the last ninety days, insiders have sold 3,205 shares of company stock worth $611,192. Insiders own 7.00% of the company’s stock.

Institutional Investors Weigh In On Ligand Pharmaceuticals

Institutional investors have recently made changes to their positions in the stock. Invesco Ltd. grew its position in shares of Ligand Pharmaceuticals by 36.5% in the fourth quarter. Invesco Ltd. now owns 516,464 shares of the biotechnology company’s stock valued at $97,648,000 after purchasing an additional 138,169 shares in the last quarter. Corient Private Wealth LLC boosted its stake in Ligand Pharmaceuticals by 339.3% in the 4th quarter. Corient Private Wealth LLC now owns 12,388 shares of the biotechnology company’s stock worth $2,342,000 after purchasing an additional 9,568 shares during the period. Summit Global Investments grew its holdings in Ligand Pharmaceuticals by 67.6% during the 4th quarter. Summit Global Investments now owns 2,417 shares of the biotechnology company’s stock valued at $457,000 after buying an additional 975 shares in the last quarter. XTX Topco Ltd purchased a new position in Ligand Pharmaceuticals during the 4th quarter valued at about $1,459,000. Finally, Voloridge Investment Management LLC increased its position in shares of Ligand Pharmaceuticals by 40.0% during the fourth quarter. Voloridge Investment Management LLC now owns 12,038 shares of the biotechnology company’s stock valued at $2,276,000 after buying an additional 3,442 shares during the period. Hedge funds and other institutional investors own 91.28% of the company’s stock.

Wall Street Analysts Forecast Growth

LGND has been the topic of several research analyst reports. Citigroup initiated coverage on Ligand Pharmaceuticals in a research report on Tuesday, December 9th. They issued a “buy” rating and a $270.00 price objective on the stock. Oppenheimer boosted their price target on shares of Ligand Pharmaceuticals from $190.00 to $250.00 and gave the stock an “outperform” rating in a report on Monday, November 3rd. Benchmark increased their price target on shares of Ligand Pharmaceuticals from $175.00 to $220.00 and gave the company a “buy” rating in a research report on Friday, November 7th. Stifel Nicolaus lifted their price objective on shares of Ligand Pharmaceuticals from $220.00 to $230.00 and gave the stock a “buy” rating in a research report on Wednesday, December 10th. Finally, Royal Bank Of Canada increased their target price on shares of Ligand Pharmaceuticals from $234.00 to $235.00 and gave the company an “outperform” rating in a research report on Wednesday, December 10th. Six investment analysts have rated the stock with a Buy rating and one has issued a Hold rating to the stock. Based on data from MarketBeat, the stock has a consensus rating of “Moderate Buy” and an average price target of $240.67.

Ligand Pharmaceuticals Company Profile

Ligand Pharmaceuticals, Inc is a biopharmaceutical company that acquires, develops and out-licenses proprietary technologies designed to help pharmaceutical and biotechnology companies discover and develop novel medicines. Operating primarily through its research services and royalty-generating businesses, Ligand focuses on building a diversified portfolio of technology platforms and partnering with industry leaders to advance therapeutic candidates across multiple disease areas.

The company’s product offerings center around several core platforms.